Clinical trial Recruiting at 1 site Interventional Ages 20 to 50

IV lidocaine versus IV dexmedetomidine for pain control during sleeve gastrectomy

Official title: Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Laparoscopic Sleeve Gastrectomy : the Effect on Recovery Outcomes Variables

Run by Alexandria University · NCT07327905 · Data updated 2026-11-12

It tests whether an IV infusion of lidocaine or dexmedetomidine given during laparoscopic sleeve gastrectomy helps reduce early postoperative pain and the need for opioid pain medicines in adults aged 20–50 with BMI 35–50.

More Bariatric Surgery trials

Quick facts

Study typeInterventional
Ages20 Years to 50 Years
SexAll
Enrollment40 (estimated)
SponsorAlexandria University
Academic / other
Locations1 site (Alexandria)
StatusRecruiting
StartedDecember 26, 2025
Main results expectedOctober 1, 2026
Study endsNovember 1, 2026
Registry record updatedJanuary 8, 2026
Trial IDNCT07327905 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 20–50 years with BMI 35–50 kg/m2, ASA class II–III, scheduled for laparoscopic sleeve gastrectomy and without contraindications to lidocaine or dexmedetomidine would be ideal candidates.

Probably not a fit

Patients with cardiac conduction disorders, cardiomyopathy, chronic opioid dependence, allergy to the study drugs, or who are pregnant or breastfeeding are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison gives participants one of two intravenous infusions—lidocaine or dexmedetomidine—around the time of laparoscopic sleeve gastrectomy. Adults aged 20–50 with BMI 35–50 and ASA physical status II–III are enrolled and monitored for pain scores, opioid consumption, sedation, and adverse events in the early postoperative period. The protocol tracks safety issues such as cardiac conduction and hemodynamic stability as well as analgesic and anti-inflammatory effects. Patients with cardiac conduction disorders, cardiomyopathy, chronic opioid use, allergy to study drugs, or pregnancy/breastfeeding are excluded.

Why it matters

Potential benefit: If successful, the approach could give better early pain relief with less opioid use and fewer opioid-related side effects after sleeve gastrectomy.

How similar studies have gone: Both intravenous lidocaine and dexmedetomidine have shown benefit in prior surgical studies for reducing postoperative pain and opioid use, but direct head-to-head data specifically in sleeve gastrectomy are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 20-50 years, both sexes.
* American Standards Association (ASA) physical status class II to III.
* Body mass index (BMI) 35-50 kg m-².

Exclusion Criteria:

* Cardiac conduction disorders.
* Cardiomyopathy.
* Chronic opioid use.
* Allergy to the studied medications.
* Pregnancy and breastfeeding.

Where it's running

  • Alexandria University
    Alexandria, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.